AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2730823 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 12048416 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep acupuncture (needle placed deeply into muscular tissue)
Number of subjects: 42
Study 12048416 — intervention group
Group type: COMPARATOR
Intervention: Superficial acupuncture (needle introduced in the skin at a depth of 2 mm)
Number of subjects: 42
Study 30646164 — intervention group
Group type: EXPERIMENTAL
Intervention: Live birth of an infant with a major congenital anomaly
Number of subjects: 42943
Study 30646164 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison cohort of randomly selected women)
Number of subjects: 42943
Study 30646164 — intervention group
Group type: EXPERIMENTAL
Intervention: Live birth of an infant with multiorgan anomalies
Number of subjects: 42943
Study 26952376 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted exercise group
Number of subjects: 60
Study 26952376 — intervention group
Group type: COMPARATOR
Intervention: Non-weighted exercise group
Number of subjects: 60
Study 23918037 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg every other week (Q2W), reduced to 200 mg Q2W after ≥6 months + Methotrexate (MTX)
Number of subjects: 958
Study 23918037 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) + Methotrexate (MTX)
Number of subjects: 958
Study 22454006 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible extended regimen with MIB (minimum 24, maximum 120 days of continuous tablet intake)
Number of subjects: 223
Study 22454006 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible extended regimen with MIB
Number of subjects: 223
Study 22454006 — intervention group
Group type: COMPARATOR
Intervention: Conventional 28-day regimen (24 active and four placebo tablets for five cycles)
Number of subjects: 223
Study 20149571 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 291
Study 20149571 — intervention group
Group type: COMPARATOR
Intervention: Change Plan completion
Number of subjects: 291
Study 18565425 — intervention group
Group type: EXPERIMENTAL
Intervention: High-selenium yeast supplementation (300 microg/d)
Number of subjects: 42
Study 18565425 — intervention group
Group type: COMPARATOR
Intervention: Placebo yeast
Number of subjects: 42
Study 16280942 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevel-up technique
Number of subjects: 396
Study 16280942 — intervention group
Group type: COMPARATOR
Intervention: Bevel-down technique
Number of subjects: 396
Study 16280942 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevel-up technique (infants < 5 kg)
Number of subjects: 396
Study 16280942 — intervention group
Group type: COMPARATOR
Intervention: Bevel-down technique (infants < 5 kg)
Number of subjects: 396
Study 12866946 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg test formulation
Number of subjects: 24
Study 12866946 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg reference formulation
Number of subjects: 24
Study 10485679 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 461
Study 10485679 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 461
Study 7851582 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate combined with hMG and FSH for ovarian stimulation
Number of subjects: 26
Study 1828570 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium entry blockers (CEB)
Number of subjects: 0
Study 7386839 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine anaesthesia
Number of subjects: 0
Study 7386839 — intervention group
Group type: COMPARATOR
Intervention: Relaxant anaesthesia
Number of subjects: 0
Study 30845995 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally laparoscopic distal gastrectomy (TLDG)
Number of subjects: 0
Study 30845995 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 0
Study 30585459 — intervention group
Group type: EXPERIMENTAL
Intervention: EA C group (3 times: one day, 30 min before and one day after surgery)
Number of subjects: 80
Study 30585459 — intervention group
Group type: COMPARATOR
Intervention: Intravenous anesthesia group
Number of subjects: 80
Study 27716303 — intervention group
Group type: EXPERIMENTAL
Intervention: Realist trials
Number of subjects: 0
Study 27716303 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 24439636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy (10% concentration inhaled for 5 minutes during 3 hemodialysis sessions)
Number of subjects: 92
Study 24439636 — intervention group
Group type: COMPARATOR
Intervention: Control group (aromatherapy free of lavender essence)
Number of subjects: 92
Study 22936194 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1 mg/kg/h plus Ketamine 5 µg/kg/min and Remifentanil 0.1 µg/kg/min (GK)
Number of subjects: 322
Study 22936194 — intervention group
Group type: COMPARATOR
Intervention: Propofol 1 mg/kg/h plus Remifentanil 0.25 µg/kg/min (GR)
Number of subjects: 322
Study 19834700 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL of 300 mgI/mL
Number of subjects: 31
Study 19834700 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mL of 370 mgI/mL
Number of subjects: 31
Study 19834700 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mL of 370 mgI/mL followed by a 30‐mL saline flush
Number of subjects: 31
Study 17393343 — intervention group
Group type: EXPERIMENTAL
Intervention: Int3 (intensified antidiabetic therapy for 3 weeks)
Number of subjects: 83
Study 17393343 — intervention group
Group type: EXPERIMENTAL
Intervention: Int52 (intensified antidiabetic therapy for 52 weeks)
Number of subjects: 83
Study 17393343 — intervention group
Group type: COMPARATOR
Intervention: Con3 (unchanged therapy for 3 weeks)
Number of subjects: 83
Study 17393343 — intervention group
Group type: COMPARATOR
Intervention: Con52 (unchanged therapy for 52 weeks)
Number of subjects: 83
Study 16235477 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 0
Study 16235477 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine with 0.5% bupivacaine
Number of subjects: 0
Study 11872998 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration-controlled therapy (zidovudine, lamivudine, and indinavir)
Number of subjects: 40
Study 11872998 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (zidovudine, lamivudine, and indinavir)
Number of subjects: 40
Study 11872998 — intervention group
Group type: COMPARATOR
Intervention: Both concentration-controlled and conventional therapy
Number of subjects: 40
Study 11686538 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid autoantibodies (TPOAb)
Number of subjects: 2249
Study 11686538 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet cell autoantibodies (ICA)
Number of subjects: 2249
Study 11686538 — intervention group
Group type: EXPERIMENTAL
Intervention: High ICA titers (> or = 20 JDF-U)
Number of subjects: 2249
Study 11686538 — intervention group
Group type: COMPARATOR
Intervention: Low ICA titers (5-19 JDF-U)
Number of subjects: 2249
Study 11686538 — intervention group
Group type: COMPARATOR
Intervention: ICA-negative sera
Number of subjects: 2249
Study 11686538 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic women (all ICA-negative)
Number of subjects: 2249
Study 9607949 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel biphasic delivery system
Number of subjects: 9
Study 9607949 — intervention group
Group type: COMPARATOR
Intervention: Liposomal delivery system
Number of subjects: 9
Study 9607949 — intervention group
Group type: COMPARATOR
Intervention: Nonliposomal (oil/water cream) delivery system
Number of subjects: 9
Study 9607949 — intervention group
Group type: COMPARATOR
Intervention: Placebo formulation
Number of subjects: 9
Study 8284002 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg at night)
Number of subjects: 65
Study 8284002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 2661222 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 25
Study 2661222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 2661222 — intervention group
Group type: COMPARATOR
Intervention: Normotensives
Number of subjects: 25
Study 781887 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone, azathioprine, and ATG
Number of subjects: 250
Study 781887 — intervention group
Group type: COMPARATOR
Intervention: Prednisone and azathioprine only
Number of subjects: 250
Study 30734476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cervical nerve root block (CRB) with mixed drug liquid
Number of subjects: 140
Study 30734476 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar looking)
Number of subjects: 140
Study 29045212 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mg tofacitinib
Number of subjects: 522
Study 29045212 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg tofacitinib
Number of subjects: 522
Study 29045212 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 522
Study 29045212 — intervention group
Group type: COMPARATOR
Intervention: placebo (switched to 5-mg tofacitinib at 3 months)
Number of subjects: 522
Study 29045212 — intervention group
Group type: COMPARATOR
Intervention: placebo (switched to 10-mg tofacitinib at 3 months)
Number of subjects: 522
Study 26899137 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini‐laparoscopic Cholecystectomy
Number of subjects: 114
Study 26899137 — intervention group
Group type: COMPARATOR
Intervention: 5mm Laparoscopic Cholecystectomy
Number of subjects: 114
Study 26899137 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini‐laparoscopic Cholecystectomy and 5mm Laparoscopic Cholecystectomy
Number of subjects: 114
Study 22642854 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care delivery
Number of subjects: 45
Study 21816921 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI) in patients with iNPH
Number of subjects: 59
Study 21816921 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticospinal tract (CST) tractographic images in patients with iNPH
Number of subjects: 59
Study 21816921 — intervention group
Group type: EXPERIMENTAL
Intervention: CST FA values in patients with iNPH
Number of subjects: 59
Study 18952164 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/day vitamin C
Number of subjects: 396
Study 18952164 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/day vitamin E
Number of subjects: 396
Study 18952164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 396
Study 16952814 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of morphine in 10 mL of saline
Number of subjects: 40
Study 16952814 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of saline
Number of subjects: 40
Study 15265057 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (maximum 100 units)
Number of subjects: 0
Study 15265057 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study 11775653 — intervention group
Group type: EXPERIMENTAL
Intervention: Essaven gel (EG)
Number of subjects: 30
Study 11775653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9322512 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-glucose (FruGlu) solution
Number of subjects: 7
Study 9322512 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-glucose-acarbose (FruGluA) solution
Number of subjects: 7
Study 9322512 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose solution
Number of subjects: 7
Study 9322512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose absorption from glucose or sucrose solutions
Number of subjects: 7
Study 9322512 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-mannitol (FruMann) solution
Number of subjects: 7
Study 9322512 — intervention group
Group type: COMPARATOR
Intervention: Sucrose, FruGlu, and glucose solutions
Number of subjects: 7
Study 8373602 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (MZ) 0.02 mg/kg i.v., repeated every 2 to 3 minutes; maintenance MZ 0.005 mg/kg i.v. as necessary
Number of subjects: 90
Study 8373602 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol bolus (PB) 0.75 to 1.0 mg/kg i.v.; maintenance 0.25 mg/kg i.v. as necessary
Number of subjects: 90
Study 8373602 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion (PI) 2 to 4 mg/kg/hr or 33 to 66 micrograms/kg/min to maintain SL3
Number of subjects: 90
Study 3539031 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised beclomethasone dipropionate suspension
Number of subjects: 16
Study 3539031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30171484 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol (12 g)
Number of subjects: 0
Study 30171484 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (control)
Number of subjects: 0
Study 27494414 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 hours time in bed (8h TIB)
Number of subjects: 58
Study 27494414 — intervention group
Group type: COMPARATOR
Intervention: 6 hours time in bed (6h TIB)
Number of subjects: 58
Study 25523303 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood induction group
Number of subjects: 60
Study 25523303 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood induction group
Number of subjects: 60
Study 25523303 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 25234606 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS) administered in 15 30-minute treatments over three weeks
Number of subjects: 0
Study 25234606 — intervention group
Group type: COMPARATOR
Intervention: Sham condition administered in 15 30-minute treatments over three weeks
Number of subjects: 0
Study 21640535 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% contrast medium (CM)
Number of subjects: 40
Study 21640535 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% contrast medium (CM)
Number of subjects: 40
Study 21640535 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% contrast medium (CM)
Number of subjects: 40
Study 21640535 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% contrast medium (CM)
Number of subjects: 40
Study 21640535 — intervention group
Group type: COMPARATOR
Intervention: All groups except 10% CM
Number of subjects: 40
Study 21640535 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (10%, 20%, 30%, 40%)
Number of subjects: 40
Study 20840526 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 756
Study 20840526 — intervention group
Group type: COMPARATOR
Intervention: Expectant monitoring
Number of subjects: 756
Study 18269775 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 1250 mg/m2 twice daily for 14 days followed by 7 days of rest
Number of subjects: 37
Study 18269775 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 1000 mg/m2 twice daily
Number of subjects: 37
Study 18269775 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity profile of capecitabine
Number of subjects: 37
Study 15691667 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium 99m stannous colloid (99mTc SnC) uptake in neutrophils
Number of subjects: 10
Study 15691667 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium 99m stannous colloid (99mTc SnC) uptake in monocytes
Number of subjects: 10
Study 15691667 — intervention group
Group type: COMPARATOR
Intervention: Blood from normal individuals incubated with lysed B. pseudomallei and colloid
Number of subjects: 10
Study 14662904 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S vaccine
Number of subjects: 20
Study 10595949 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐sestamibi injection (20 to 30 mCi) before primary angioplasty
Number of subjects: 61
Study 8730912 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive one-on-one education about anxiety and periodic feedback about patients with anxiety (Intervention)
Number of subjects: 637
Study 8730912 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 637
Study 8730912 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive one-on-one education about anxiety (Intervention)
Number of subjects: 637
Study 1878612 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped behavioral treatment program
Number of subjects: 0
Study 1878612 — intervention group
Group type: COMPARATOR
Intervention: Videotaped placebo program
Number of subjects: 0
Study 1878612 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 0
Study 6682026 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusion at a rate of 20 micrograms kg‐1 hr‐1
Number of subjects: 14
Study 6682026 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusion
Number of subjects: 14
Study 6682026 — intervention group
Group type: COMPARATOR
Intervention: Control group (no naloxone)
Number of subjects: 14
Study 3887976 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tiaramide 200 mg four times daily
Number of subjects: 35
Study 3887976 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salbutamol 4 mg four times daily
Number of subjects: 35
Study 3887976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 3887976 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tiaramide
Number of subjects: 35
Study 30063148 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal scrub technique
Number of subjects: 163
Study 30063148 — intervention group
Group type: COMPARATOR
Intervention: Fones technique
Number of subjects: 163
Study 26906526 — intervention group
Group type: EXPERIMENTAL
Intervention: Anamorelin 100 mg orally once daily
Number of subjects: 979
Study 26906526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 979
Study 25355194 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg once daily
Number of subjects: 45
Study 25355194 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol/acetaminophen 500 mg thrice daily
Number of subjects: 45
Study 25355194 — intervention group
Group type: COMPARATOR
Intervention: Placebo (empty capsules)
Number of subjects: 45
Study 22762072 — intervention group
Group type: EXPERIMENTAL
Intervention: Female GPs
Number of subjects: 4467
Study 22762072 — intervention group
Group type: EXPERIMENTAL
Intervention: Time, caring, involving the patient in decisions, putting the patient at ease, language, lower education, age >25 years, current fear
Number of subjects: 4467
Study 20158920 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic-based exercise training (6 months, thrice-weekly)
Number of subjects: 70
Study 20158920 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study 18815543 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 2621
Study 18815543 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 2621
Study 18815543 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (in large-scale trials >200 cases)
Number of subjects: 2621
Study 16637745 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who held a pen in their mouths to inhibit imitation of the faces.
Number of subjects: 0
Study 16637745 — intervention group
Group type: COMPARATOR
Intervention: Control participants who could imitate freely.
Number of subjects: 0
Study 11266148 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive, 18-month life-style intervention program
Number of subjects: 128
Study 11266148 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study 9895267 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TVP)
Number of subjects: 76
Study 9895267 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 76
Study 7994169 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomic failure patients
Number of subjects: 25
Study 7994169 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe autonomic failure and orthostatic hypotension
Number of subjects: 25
Study 7994169 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 25
Study 2500169 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg twice daily for 16 weeks
Number of subjects: 60
Study 2500169 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg twice daily for 16 weeks
Number of subjects: 60
Study 2500169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (run-in period of 4-6 weeks)
Number of subjects: 60
Study 815189 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg, three times a day for 2 days)
Number of subjects: 50
Study 815189 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 50
Study 815189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31884074 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating level of IGF1
Number of subjects: 397380
Study 31884074 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic factors predicting IGF1 level
Number of subjects: 397380
Study 31884074 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic factors predicting IGFBP3 level
Number of subjects: 397380
Study 29652761 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 38
Study 29652761 — intervention group
Group type: COMPARATOR
Intervention: Control (breathing training only)
Number of subjects: 38
Study 27039022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 455
Study 27039022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg with laser
Number of subjects: 455
Study 27039022 — intervention group
Group type: COMPARATOR
Intervention: Laser only
Number of subjects: 455
Study 25198813 — intervention group
Group type: EXPERIMENTAL
Intervention: Power‐injectable PICCs with Solo‐2 proximal valve (Bard)
Number of subjects: 180
Study 25198813 — intervention group
Group type: EXPERIMENTAL
Intervention: Power‐injectable PICCs with PASV proximal valve (Navilyst)
Number of subjects: 180
Study 25198813 — intervention group
Group type: COMPARATOR
Intervention: Non‐valved power‐injectable PICCs (Medcomp)
Number of subjects: 180